First Republic Investment Management Inc. lifted its holdings in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 242,318 shares of the financial services provider’s stock after buying an additional 5,457 shares during the period. First Republic Investment Management Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $29,548,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Bailard Inc. raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 20.6% in the third quarter. Bailard Inc. now owns 5,302 shares of the financial services provider’s stock valued at $647,000 after acquiring an additional 905 shares in the last quarter. Wedbush Securities Inc. lifted its holdings in iShares Nasdaq Biotechnology ETF by 26.6% in the third quarter. Wedbush Securities Inc. now owns 3,547 shares of the financial services provider’s stock valued at $433,000 after acquiring an additional 745 shares during the period. People s United Financial Inc. raised its stake in shares of iShares Nasdaq Biotechnology ETF by 34.2% during the 3rd quarter. People s United Financial Inc. now owns 95,694 shares of the financial services provider’s stock worth $11,656,000 after buying an additional 24,389 shares during the period. Cahill Financial Advisors Inc. increased its position in shares of iShares Nasdaq Biotechnology ETF by 51.9% during the third quarter. Cahill Financial Advisors Inc. now owns 2,926 shares of the financial services provider’s stock worth $357,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Proequities Inc. purchased a new stake in shares of iShares Nasdaq Biotechnology ETF during the third quarter worth approximately $843,000. Hedge funds and other institutional investors own 63.65% of the company’s stock.

IBB opened at $106.88 on Friday. iShares Nasdaq Biotechnology ETF has a 12-month low of $100.22 and a 12-month high of $122.97.

TRADEMARK VIOLATION NOTICE: “iShares Nasdaq Biotechnology ETF (IBB) Shares Bought by First Republic Investment Management Inc.” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/ishares-nasdaq-biotechnology-etf-ibb-shares-bought-by-first-republic-investment-management-inc/2667795.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.